152 related articles for article (PubMed ID: 1856513)
1. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
[TBL] [Abstract][Full Text] [Related]
2. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
[TBL] [Abstract][Full Text] [Related]
3. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
4. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M
Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185
[No Abstract] [Full Text] [Related]
5. The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer.
Barillari P; Ramacciato G; de Angelis R; Gozzo P; Aurello P; Indinnimeo M; Valabrega S; D'Angelo F; Fegiz G
Int J Colorectal Dis; 1989 Dec; 4(4):230-3. PubMed ID: 2693562
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
8. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
[TBL] [Abstract][Full Text] [Related]
9. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
10. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
11. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma].
Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M
Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409
[TBL] [Abstract][Full Text] [Related]
12. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
14. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
van Dalen A
Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
[TBL] [Abstract][Full Text] [Related]
15. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
[TBL] [Abstract][Full Text] [Related]
16. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Sölétormos G; Petersen PH; Dombernowsky P
Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
19. CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA.
Torres M; Pacheco C; Valverde A; Rebollo AC; Moral A; Vallejo JA; Mateo A
Int J Biol Markers; 1995; 10(2):94-9. PubMed ID: 7561245
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation.
Sölétormos G; Schiøler V; Nielsen D; Skovsgaard T; Dombernowsky P
Clin Chem; 1993 Oct; 39(10):2077-83. PubMed ID: 8403393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
